Filing Flows › 60 Degrees Pharmaceuticals (SXTP) › Q2 2025
60 Degrees Pharmaceuticals (SXTP) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
60 Degrees Pharmaceuticals (SXTP) reported revenue of $101K for the second quarter 2025 (Q2 2025), -19% from a year earlier and -38% from the quarter before.
60 Degrees Pharmaceuticals, Q2 2025: revenue $101K (-19% year over year), net loss $1.7M, operating cash flow −$1.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $101K | -38% | -19% |
| Operating profit | −$1.6M | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | −$1.5M | — | — |
What changed
Revenue was $101K in Q2 2025, down 19% year over year and down 38% from the previous quarter.
Gross margin was 50.4%, up 22.1 points from a year earlier. Operating costs exceeded revenue by $1.6M, an operating margin of -1591.5%. Operating expenses fell 61% while revenue fell 19%. The quarter ended with a net loss of $1.7M, narrower than the previous quarter's $1.9M loss. Minority interests bore $1K of it: to shareholders the quarter was a loss of $1.7M.
Operating cash flow was −$1.5M. Non-cash charges added back $20K of depreciation and amortization and $79K of share-based compensation. Working capital and other items added $187K. Capital expenditures of $47K exceeded it, leaving free cash flow of −$1.5M.
Questions
What was 60 Degrees Pharmaceuticals' revenue in the second quarter 2025?
60 Degrees Pharmaceuticals (SXTP) reported revenue of $101K for the second quarter 2025 (Q2 2025), -19% from a year earlier and -38% from the quarter before.